Tumor Suppressing Viruses, Genes, and Drugs (eBook, PDF)

Innovative Cancer Therapy Approaches
Redaktion: Maruta, Hiroshi

• Format: PDF

Produktbeschreibung

Tumor Suppressing Viruses, Genes, and Drugs profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 425
• Erscheinungstermin: 3. Dezember 2001
• Englisch
• ISBN-13: 9780080549026
• Artikelnr.: 38124532

Inhaltsangabe

Contributors

Preface

1 Oncolytic Viruses: Virotherapy for Cancer

I. Introduction

II. Attributes of Replication-Selective Viruses for Cancer Treatment

III. Approaches to Optimizing Tumor-Selective Viral Replication

IV. Adenoviruses

V. Poliovirus

VI. Vesicular Stomatitis Virus

VII. Reovirus

VIII. Bacteria

IX. Vaccinia Virus

X. Herpesvirus

XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients

XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042)

XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents

XIV. Summary

References

2 Reovirus Therapy of Ras-Associated Cancers

I. Introduction

II. Reovirus Oncolysis

III. Concluding Remarks

References

3 Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical

I. Introduction

II. Preclinical Studies of G207

III. G207 Clinical Trial

IV. Conclusions

References

4 p53 and Its Targets

I. Introduction

II. Activation of p53

III. Downstream Mediators of p53

References

5 Prospects for Tumor Suppressor Gene Therapy: RB as an Example

I. Introduction

II. Functions of RB

III. Successes with RB Gene Therapy

IV. Perspectives

References

6 CDK Inhibitors: Genes and Drugs

I. Introduction

II. G1 Regulation

III. p16INK4a and the Rb Pathway

IV. p19ARF and p53 Pathway

V. p27 and Human Cancer

VI. Conclusions and Future Perspectives

References

7 CDK Inhibitors: Small Molecular Weight Compounds

I. Introduction

II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer

III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures

IV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP

V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem

VI. Cyclin-Dependent Kinase Inhibitors, Cellular Effects

VII. Cyclin-Dependent Kinase Inhibitors, Antitumor Activity

VIII. Conclusion

References

8 NF1 and Other RAS-Binding Peptides

I. RAS Molecules: Normal versus Oncogenic Mutants

II. Super GAP?

III. RAS-Binding Fragment of NF1

IV. c-RAF-1

V. PI-3 Kinase

VI. Ral GDS

References

9 Cytoskeletal Tumor Suppressor Genes

I. Introduction (Historical Background)

II. Type I Cytoskeletal Tumor Suppressors

III. Type II Cytoskeletal Tumor Suppressors

References

10 TGF-? Signaling and Carcinogenesis

I. Introduction

II. Dual Role of TGF-? in Carcinogenesis

III. TGF-? Superfamily Signaling

IV. Perturbation of TGF-? Signaling in Cancer Cells

V. Perspectives

References

11 DAN Gene

I. Introduction

II. Cloning of DAN cDNA

III. Transfection of DAN

IV. Role of DAN in Neuroblastomas

V. Structural Features of the DAN Protein

VI. Genomic Structure of DAN

VII. DAN Family

References

12 Design of Hammerhead Ribozymes and Allosterically Controllable Maxizymes for Cancer Gene Therapy

I. Introduction

II. Ribozyme Expression System in Cells

III. Design of the tRNAVal-Driven Ribozyme That Is Transcribed by pol III

IV. Design of Allosterical

Rezensionen

"...a brave attempt to encompass a broad, exciting and developing field." --MICROBIOLOGY TODAY (2003)